2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow copanlisib: new trials by email Literature Review of copanlisib trials Research Report on copanlisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Copanlisib (BAY80-6946), Placebo, Rituximab - Lymphoma, Non-Hodgkin | Phase 3 | Terminated | Bayer | 551 | 2016-01-06 | 2024-12-11 |
| Phase III Copanlisib in Rituximab-refractory iNHL Copanlisib (BAY 80-6946) - Lymphoma, Non-Hodgkin | Phase 3 | Completed | Bayer | 25 | 2015-09-22 | 2023-11-18 |
| Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab - Lymphoma,Non-Hodgkin | Phase 3 | Completed | Bayer | 458 | 2015-08-03 | 2025-10-14 |
Bayer (3)
Brazil (3) · Bulgaria (3) · Greece (3) · Italy (3) · Poland (3) · Russia (3) · South Africa (3) · South Korea (3) · Taiwan (3) · Turkey (Türkiye) (3) · Australia (2) · Belgium (2) · Chile (2) · China (2) · France (2)
PMID 33848462, PMID 34389273, PMID 38226495, PMID 39058951
2014 (1), 2015 (1)